संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

agila specialties private limited - vancomycin hydrochloride (unii: 71wo621tjd) (vancomycin - unii:6q205eh1vu) - vancomycin 10 g in 100 ml

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - vancomycin hydrochloride, quantity: 268 mg (equivalent: vancomycin, qty 250 mg) - capsule, hard - excipient ingredients: macrogol 6000; titanium dioxide; brilliant blue fcf; maize starch; purified water; purified talc; iron oxide yellow; gelatin; sodium lauryl sulfate; ethanol; shellac; carnauba wax; 1-butanol; glyceryl monooleate - vancomycin bnm capsules may be administered orally for the treatment of staphylococcal enterocolitis and antibiotic-associated pseudomembranous colitis produced by c. difficile. parenteral administration of vancomycin is not effective for the above indications; therefore vancomycin bnm must be given orally. vancomycin bnm is not effective by the oral route for other types of infection.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - vancomycin hydrochloride, quantity: 134 mg (equivalent: vancomycin, qty 125 mg) - capsule, hard - excipient ingredients: macrogol 6000; titanium dioxide; ethanol; shellac; carnauba wax; 1-butanol; glyceryl monooleate; brilliant blue fcf; maize starch; purified water; purified talc; gelatin; sodium lauryl sulfate; tartrazine - vancomycin bnm capsules may be administered orally for the treatment of staphylococcal enterocolitis and antibiotic-associated pseudomembranous colitis produced by c. difficile. parenteral administration of vancomycin is not effective for the above indications; therefore vancomycin bnm must be given orally. vancomycin bnm is not effective by the oral route for other types of infection.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

cardinal health - vancomycin hydrochloride (unii: 71wo621tjd) (vancomycin - unii:6q205eh1vu) - vancomycin 500 mg in 100 ml

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

civica, inc. - vancomycin hydrochloride (unii: 71wo621tjd) (vancomycin - unii:6q205eh1vu) - vancomycin hydrochloride for injection, usp is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (ß-lactam-resistant) staphylococci. it is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. vancomycin hydrochloride for injection, usp is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. vancomycin hydrochloride for injection, usp is effective in the treatment of staphylococcal endocarditis. its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. when staphylococcal infecti

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

viatris limited - vancomycin hydrochloride 513mg equivalent to 500 mg vancomycin;  ;  ;   - powder for infusion - 500 mg - active: vancomycin hydrochloride 513mg equivalent to 500 mg vancomycin       - vancomycin hydrochloride is indicated for potentially life-threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins. vancomycin hydrochloride is useful in therapy of severe staphylococcal (including methicillin resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. vancomycin hydrochloride is effective alone or in combination with an aminoglycoside for endocarditis caused by streptococcus viridans or s. bovis. for endocarditis caused by enterococci (e.g. strep. faecalis), vancomycin hydrochloride is effective only in combination with an aminoglycoside. vancomycin hydrochloride is effective for the treatment of diptheroid endocarditis. vancomycin hydrochloride is used in combination with rifampicin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by staph. epidermidis or diptheroids. the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures. specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin hydrochloride. vancomycin hydrochloride should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic-associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin hydrochloride alone is inappropriate for this indication.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - vancomycin hydrochloride (unii: 71wo621tjd) (vancomycin - unii:6q205eh1vu) - vancomycin hydrochloride is indicated for the treatment of clostridium difficil e‑associated diarrhea in adults and pediatric patients less than 18 years of age. vancomycin hydrochloride is also indicated for the treatment of enterocolitis caused by staphylococcus aureus (including methicillin‑resistant strains) in adults and pediatric patients less than 18 years of age. important limitations of use to reduce the development of drug‑resistant bacteria and maintain the effectiveness of vancomycin hydrochloride and other antibacterial drugs, vancomycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. vancomycin hydrochloride is contraindicated in patients with kn

माल्टा - अंग्रेज़ी - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - vancomycin hydrochloride - powder for concentrate for solution for infusion - vancomycin hydrochloride 500 mg - antibacterials for systemic use

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 1025.2 mg - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 512.6 mg - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.